GSK343 treatment decreased DNMT3A recruitment to the ULBP1 ligand promoter, reducing promoter DNA methylation and increasing ULBP1 expression, further elucidating the role of EZH2 as an inhibitor of anti-tumor immune responses (135). The gene discussed is EZH2; the disease is neoplasm.